ComtecMed Medical Congresses is delighted to invite you to take part in the very 1st Meeting on Controversies in preconception, preimplantation and prenatal genetic diagnosis: How will genetics technology drive the future? (CoGEN), taking place September 25 – 27, 2015 in Paris, France at the Novotel Paris Tour Eiffel Hotel.
The ongoing reduction in the costs of genome sequencing has brought us a giant step closer to the point in which personal genome sequencing for fertility will be standard. Medical and scientific professionals must develop ways to help physicians leverage genome information for the benefit of their patients. The personalized medicine vision that is quickly becoming reality is based heavily on computational biomedicine.
This quickly advancing discipline processes, integrates and analyzes genomic, clinical and molecular information. Methods developed in this field have already instigated a revolution, not just in biomedical research and theory, but also in our ability to diagnose incurable diseases and develop appropriate treatments. The objectives of this conference are twofold: to enhance our ability to provide genetic counseling to couples interested in getting pregnant, and to evaluate embryo genetics in order to increase oocyte implantation effectiveness and optimize early diagnosis of genetic diseases.
- Introduction to Genetics
- Basic principles for the non-geneticist
- Next generation sequencing: strategies for genetic testing
- Technical aspects of reproductive genetics (Methods of PGS, PGD, Prenatal)
- Carrier screening of recessive disease: Universal screening
- PGD and PGS: State-of-the-Art
- Development and current best practice for translocations
- Single gene diagnosis and aneuploidy detection using karyomapping
- Clinically evaluating NGS and its extra information
- PGS for advanced maternal age
- The clinical value of Preimplantation Genetic Screening (PGS)
- Management of PGS treatment embryo: timing, technology, success and cost effectiveness
- Aneuploidy in embryos: variability between centers, between patients and between cycles of the same patients
- Debate: Is it now unethical not to screen out an aneuploidy embryo in IVF?
- Prediction of Gamete quality and viability
- Cumulus cell genomics and its predictive value
- Blastocoel analysis for PGS and the potential clinical value of mitochondrial screening assays
- Ultra-sensitive mass spectrometry to look at the proteomic content of the blastocoel fluid with a view to embryo viability assessment
- Update on polar body testing for detection of female meiotic errors
- Non-Invasive Prenatal Testing (NIPT): Current state of the ART
- Introduction of NIPT in clinical practice
- Debate: How should NIPT be used: (a) As primary screening to all patients (b) As contingent screening in very high and intermediate risk patients
- Non-Invasive Prenatal Testing (NIPT): Future Perspectives
- Debate: NIPT for microdeletion syndromes – Pros and Cons
- NIPT for Single-Gene Disorders
- Future development in NIPT
- Chromosomal microarrays (CMA) in Prenatal Diagnosis
- Chromosomal microarrays — how does it work?
- Can CMA replace standard karyotyping?
- Counseling for Variants of Unclear Clinical Significance
- Debate: Would it be ethical not to propose women to undergo invasive testing with CMA? For/Against
- Genetics in infertility
- Characterization of the molecular etiology of severe cases of infertility — a must to bring personalized medicine to the field of reproduction
- Carrier screening of genes relevant in infertility, including mutations associated with miscarriage
- Gene therapy in reproductive medicine
- Social and legal aspects
- Simon Fishel, UK
- Luca Gianaroli, Italy
- Tony Gordon, UK
- Alan Handyside, UK
- Gary Harton, USA
- Ariel Hourvitz, Israel
- Mark Hughes, USA
- Santiago Munné, USA
- Svetlana Rechitsky, USA
- Richard Scott, USA
- Zeev Shoham, Israel
- Gabor Vajta, Australia
- Ariel Weissman, Israel
- Dagan Wells, UK
- Yuval Yaron, Israel
We will be applying for CME accreditation for the ‘1st Meeting on Controversies in preconception, preimplantation and prenatal genetic diagnosis: How will genetics technology drive the future? (CoGEN)‘
ABPI Compliance Policy
The organizers of the ‘1st Meeting on Controversies in preconception, preimplantation and prenatal genetic diagnosis: How will genetics technology drive the future? (CoGEN)’ recognize the ABPI Code of Practice and the implications this has for pharmaceutical companies that support the meeting.
ABPI compliance policy for the The ‘1st Meeting on Controversies in preconception, preimplantation and prenatal genetic diagnosis: How will genetics technology drive the future? (CoGEN)‘
Funds generated from exhibition space and sponsorship are used solely to cover costs of the venue and logistical arrangements and do not fund any element of any social events. Support from pharmaceutical companies is clearly indicated in promotional and conference materials.
Evening networking events are arranged separately from the conference. They are aimed only at registered delegates and are not publicly advertised. They are funded solely by the sale of tickets to registered delegates.